Trending...
- Bob Holz New Video with Darryl Jones of the Rolling Stones, Concert, Album and Endorsement
- Immediate Therapy for Urinary Incontinence in Women
- SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in Ryvyl Inc. with Losses of $100,000 to Contact the Firm
LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that on December 3, 2022, the Compensation Committee of Puma's Board of Directors approved the grant of inducement restricted stock unit awards covering 20,625 shares of Puma common stock to three new non-executive employees.
The awards were granted under Puma's 2017 Employment Inducement Incentive Award Plan, which was adopted on April 27, 2017 and provides for the granting of equity awards to new employees of Puma. The restricted stock unit awards vest over a three-year period, with one-third of the shares underlying each award vesting on the first anniversary of the award's vesting commencement date, December 1, 2022, and one-sixth of the shares underlying each award vesting on each six-month anniversary of the vesting commencement date thereafter, subject to continued service. The awards were granted as an inducement material to the new employees entering into employment with Puma, in accordance with Nasdaq Listing Rule 5635(c)(4).
More on The Californer
About Puma Biotechnology
Puma Biotechnology, Inc. is a biopharmaceutical company with a focus on the development and commercialization of innovative products to enhance cancer care. Puma in-licenses the global development and commercialization rights to PB272 (neratinib, oral), PB272 (neratinib, intravenous) and PB357. Neratinib, oral was approved by the U.S. Food and Drug Administration in 2017 for the extended adjuvant treatment of adult patients with early stage HER2-overexpressed/amplified breast cancer, following adjuvant trastuzumab-based therapy, and is marketed in the United States as NERLYNX® (neratinib) tablets. In February 2020, NERLYNX was also approved by the FDA in combination with capecitabine for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2-based regimens in the metastatic setting. NERLYNX was granted marketing authorization by the European Commission in 2018 for the extended adjuvant treatment of adult patients with early stage hormone receptor-positive HER2-overexpressed/amplified breast cancer and who are less than one year from completion of prior adjuvant trastuzumab-based therapy. NERLYNX is a registered trademark of Puma Biotechnology, Inc.
More on The Californer
In September 2022, Puma entered into an exclusive license agreement for the development and commercialization of the anti-cancer drug alisertib, a selective, small molecule, orally administered inhibitor of aurora kinase A. Initially, Puma intends to focus the development of alisertib on the treatment of small cell lung cancer and breast cancer.
Contacts
Alan H. Auerbach or Mariann Ohanesian, Puma Biotechnology, Inc., +1 424 248 6500
info@pumabiotechnology.com
ir@pumabiotechnology.com
The awards were granted under Puma's 2017 Employment Inducement Incentive Award Plan, which was adopted on April 27, 2017 and provides for the granting of equity awards to new employees of Puma. The restricted stock unit awards vest over a three-year period, with one-third of the shares underlying each award vesting on the first anniversary of the award's vesting commencement date, December 1, 2022, and one-sixth of the shares underlying each award vesting on each six-month anniversary of the vesting commencement date thereafter, subject to continued service. The awards were granted as an inducement material to the new employees entering into employment with Puma, in accordance with Nasdaq Listing Rule 5635(c)(4).
More on The Californer
- American Vanguard Announces Preliminary Unaudited Full Year 2022 Financial Highlights
- California: Governor Newsom Honors Two CHP Officers With Medal of Valor
- California: Governor Newsom Names Sean Duryee CHP Commissioner
- California: Governor Newsom Calls Out Big Oil on Continued Push for Drilling in Neighborhoods
- City of Long Beach to Provide Sanitation and Water Filling Services to People Living in Recreational Vehicles
About Puma Biotechnology
Puma Biotechnology, Inc. is a biopharmaceutical company with a focus on the development and commercialization of innovative products to enhance cancer care. Puma in-licenses the global development and commercialization rights to PB272 (neratinib, oral), PB272 (neratinib, intravenous) and PB357. Neratinib, oral was approved by the U.S. Food and Drug Administration in 2017 for the extended adjuvant treatment of adult patients with early stage HER2-overexpressed/amplified breast cancer, following adjuvant trastuzumab-based therapy, and is marketed in the United States as NERLYNX® (neratinib) tablets. In February 2020, NERLYNX was also approved by the FDA in combination with capecitabine for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2-based regimens in the metastatic setting. NERLYNX was granted marketing authorization by the European Commission in 2018 for the extended adjuvant treatment of adult patients with early stage hormone receptor-positive HER2-overexpressed/amplified breast cancer and who are less than one year from completion of prior adjuvant trastuzumab-based therapy. NERLYNX is a registered trademark of Puma Biotechnology, Inc.
More on The Californer
- SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in Atlassian Corporation with Losses of $100,000 to Contact the Firm
- Dream Foundation Keeps Terminally-Ill Couple Connected With Their Final Dream
- PriceSmart Announces 7.0% Increase to Semi-Annual Dividend; Voting Results from the 2023 Annual Meeting of Stockholders; Appointment of New Director
- Additional Winter Shelter Doubling City's Capacity to Open in West Long Beach in February
- Texas Automotive Lift & Equipment Distributor chooses Employees Ownership
In September 2022, Puma entered into an exclusive license agreement for the development and commercialization of the anti-cancer drug alisertib, a selective, small molecule, orally administered inhibitor of aurora kinase A. Initially, Puma intends to focus the development of alisertib on the treatment of small cell lung cancer and breast cancer.
Contacts
Alan H. Auerbach or Mariann Ohanesian, Puma Biotechnology, Inc., +1 424 248 6500
info@pumabiotechnology.com
ir@pumabiotechnology.com
Filed Under: Business
0 Comments
Latest on The Californer
- SET Announces Groundbreaking Solar Boost Technology
- Soft Treats That Older Dogs Can Sink Their Teeth Into
- California: Governor Newsom Announces Appointments 2.2.23
- The 10 Principles Of Economics And How They Can Benefit You
- HVAC Alliance Expert Offers Reliable Central Heating System Installation Across California and New York
- California: Governor Newsom on Fifth Circuit Court Ruling Allowing Domestic Violence Abusers to Possess Guns
- Louisville Riverport Authority Applies To Include South Central Kentucky In Foreign Trade Zone #29 Service Area
- Meditation Doesn't Help Just the Mind, But the Body Too
- Industry Raises $183,000+ To Support Canine Assistance Organization To Help Veterans
- Getaround Announces Restructuring Plan to Reduce Costs and Streamline Operations
- Registration Now Open for Display Week 2023 in Los Angeles
- Metropolitan Board Names New General Auditor
- February Virtual Author Talks from the Long Beach Public Library
- ReserveBar Receives 2022 "Retailer/Marketplace of the Year" Award by Wine Enthusiast Magazine
- Snell & Wilmer Partner Rose Sorensen Appointed to LA Area Chamber of Commerce Board of Governors
- IntellaTriage Hires New Director of Clinical Operations
- Suffolk Hires Brad Denney as West Region Chief Operating Officer in Northern California to Support Further Growth
- Axiomtek and Sodaclick Announce Partnership to Deliver Incredible Smart Retail Solutions
- Long Beach City Council Approves Development of a Natural Gas Price-Spike Relief Program for City Residential Gas Customers in Need
- Pasternack Launches New Waveguide Mixers, Detectors and Couplers